Abstract
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors or “statin” medications are the most commonly prescribed therapy for lowering cholesterol. In use for over a decade, they have demonstrated both safety and tolerability across a broad range of patients. The ability to inhibit the biosynthesis of cholesterol and reduce low-density lipoprotein cholesterol levels is known to play a major part in reducing cardiovascular risk. Multiple clinical trials have cemented their role in both primary and secondary prevention of atherosclerotic disease. Clinical evidence also supports the principle that reductions in cardiovascular risk are interdependent on mechanisms beyond cholesterol reduction alone. These pleiotropic effects of statins have underscored a widening focus and understanding into the mechanisms of vascular dysfunction, inflammation, and injury. They have also brought a new perspective to a broad spectrum of clinical uses that has implications for specialties as varied as infectious disease, rheumatology, and oncology.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Endo A, Kuroda M, Tsujita Y: ML-236A, ML-236B and ML-236C, new inhibitors of cholesterolgenesis produced by Penicillium citrinum. J Antibiot 1976, 29:1346–1348.
Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383–1389.
Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301–1307.
Sacks FM, Pfeffer MA, Lemuel A: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001–1009.
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349–1357.
Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998, 279:1615–1622.
Vaughan CJ, Murphy MB, Buckley BM: Statins do more than just lower cholesterol. Lancet 1996, 348:1079–1082.
Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 1990, 343:425–430.
Bellosta S, Ferri N, Bernini F, et al.: Non-lipid-related effects of statins. Ann Med 2000, 32:164–176.
Schonbeck U, Libby P: Inflammation, immunity, and HMG-CoA reductase inhibitors. Circulation 2004, 109:II-18–II-26.
Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med 1999, 340:115–126.
Cayatte AJ, Palacino JJ, Horten K, et al.: Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994, 14:753–759.
Hamon M, Vallet B, Bauters C, et al.: Long-term oral administration of L-arginine reduces intimal thickening and enhances neoendothelium-dependent acetylcholine-induced relaxation after arterial injury. Circulation 1994, 90:1357–1362.
O’Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-CoA reductase inhibitor, improves endothelial function within 1 month. Circulation 1997, 95:1126–1131.
Newby DE, Wright RA, Labinjoh C, et al.: Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking. Circulation 1999, 99:1411–1415.
Panza JA, Garcia CE, Kilcoyne CM, et al.: Impaired endothelium-dependent vasodilation in patients with essential hypertension: Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 1995, 91:1732–1738.
Kawano H, Motoyama T, Hirashima O, et al.: Hyperglycemia rapidly supresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999, 34:146–154.
Liao JK, Bettmann MA, Sandor T, et al.: Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. Circ Res 1991, 68:1027–1034.
Radomski MW, Palmer RM, Moncada S: An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A 1990, 87:5193–5197.
Garg UC, Hassid A: Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989, 83:1774–1777.
Kubes P, Suzuki M, Granger DN: Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 1991, 88:4651–4655.
Brown D, London E: Structure and function of sphingolipid and cholesterol-rich membrane rafts. J Biol Chem 2000, 275:17221–17224.
Feron O, Saldana F, Michel JB, et al.: The endothelial nitricoxide synthase-caveolin regulatory cycle. J Biol Chem 1998, 273:3125–3128.
Tamai O, Matsuoka H, Itabe H, et al.: Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997, 95:76–82.
Harris MB, Blackstone MA, Sood SG, et al.: Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physiol 2004, 287:H560-H566.
Takemoto M, Liao, J: Pleiotropic effects of 3-hydroxy-3-Methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001, 21:1712–1719.
Feron O, Dessy C, Desager JP, et al.: Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001, 103:113–118.
Vergnani L, Hatrik S, Ricci F, et al.: Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: key role of L-arginine availability. Circulation 2000, 101:1261–1266.
Rikitake Y, Kawashima S, Takeshita S, et al.: Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001, 154:87–96.
Ohara Y, Peterson TE, Harrison DG: Hypercholseterolemia increases endothelial superoxide anion production. J Clin Invest 1993, 91:2546–2551.
Aikawa M, Voglic SJ, Sugiyama S, et al.: Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation 1999, 100:1215–1222.
Ridker PM, Rifai N, Rose L, et al.: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557–1565.
Ridker PM, Rifai N, Clearfield M, et al.: Measurement of C-reactive protein for the targeting of statin therapy in the prevention of acute coronary events. N Engl J Med 2001, 344:1959–1965.
Weber C, Erl W, Weber KS, et al.: HMG-CoA recuctase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypecholesterolemia. J Am Coll Cardiol 1997, 30:1212–1217.
Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001, 7:687–692.
Martinez-Gonzalez J, Alfon J, Berrozpe M, et al.: HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolic swine independently of their effect on plasma cholesterol levels. Atherosclerosis 2001, 159:27–33.
Guijarro C, Blanco-Colio LM, Ortego M, et al.: 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998, 83:490–500.
Isner J: Apoptosis in human atherosclerosis and restenosis. Circulation 1995, 91:2703–2711.
Weis M, Heeschen C, Glassford A, et al.: Statins have biphasic effects on angiogenesis. Circulation 2002, 105:739–745.
von der Thusen JH, van Vlijmen BJ, Hoeben RC, et al.: Induction of atherosclerotic plaque rupture in apoliproprotein E-/- mice after adenovirus-mediated transfer of p53. Circulation 2002, 105:2064–2070.
Crisby M, Nordin-Fredriksson G, Shah PK, et al.: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001, 103:926–933.
Stoneman V, Bennett M: Role of apoptosis in atherosclerosis and its therapeutic implications. Clin Sci 2004, 86:1–23.
Aikawa M, Rabkin E, Sugiyama S, et al.: An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001, 103:276–283.
Essig M, Nguyen G, Prie D, et al.: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res 1998, 83:683–690.
Bourcier T, Libby P: HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 2000, 20:556–562.
Vaughan CJ, Gotto AM Jr, Basson CT: The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000, 35:1–10.
Degraeve F, Bolla M, Blaie S, et al.: Modulation of COX-2 expression by statins in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins. J Biol Chem 2001, 276:46849–46855.
Almog Y, Shefer A, Novack V, et al.: Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004, 110:880–885.
Node K, Fujita M, Kitakaze M, et al.: Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003, 108:839–843.
Kobashigawa J, Katznelson S, Laks H, et al.: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995, 333:621–627.
Bennett MR: Apoptosis of vascular smooth muscle cells in vascular remodeling and atherosclerotic plaque rupture. Cardiovasc Res 1999, 41:361–368.
Kureishi Y, Luo Z, Shiojima I, et al.: The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nature Med 2000, 6:1004–1010.
Sata M, Nishimatsu H, Osuga J, et al.: Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension 2004, 43:1214–1220.
Bjere LM, LeLorier J: Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med 2001, 110:716–723.
Wong WW, Dimitroulakos J, Minden MD, et al.: HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002, 16:508–519.
Poynter J: HMG CoA reductase inhibitors and the risk of colorectal cancer. Presented at the 2004 American Society of Clinical Oncology. New Orleans, June 5–8, 2004.
Vollmer T, Lyndon K, Durkalski V, et al.: Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004, 363:1607–1608.
Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, et al.: Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 2003, 12:607–611.
Waldman A, Kritharides L: The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia. Drugs 2003, 63:139–152.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garcia, P.J. Pleiotropic effects of statins: Moving beyond cholesterol control. Curr Atheroscler Rep 7, 34–39 (2005). https://doi.org/10.1007/s11883-005-0073-6
Issue Date:
DOI: https://doi.org/10.1007/s11883-005-0073-6